The difficult manufacturing process for follow-on biologics may discourage companies
This article was originally published in The Gold Sheet
Doug Long, vice president of industry relations for IMS Health, made this prediction at a recent policy meeting sponsored by the Generic Pharmaceutical Association in Washington. Long asserted that while the EU currently has a regulatory approval system for follow-on biologics and will be ahead of the U.S. in developing these products, "U.S. manufacturers will not be far behind." And two key House health legislators, reps. Frank Pallone, D-N.J., and Henry Waxman, D-Calif., asserted at the meeting that Congress will enact an approval pathway for generic biologics this year
You may also be interested in...
The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.
The robotic surgery company recorded $1.29bn in first-quarter revenue, an 18% year-over-year increase. Worldwide da Vinci procedures were up 16% as surgical volumes recovered from the pandemic.
The Department of Toxic Substances Control does not identify specific chemicals of concern in its 2021-2023 Priority Product Draft Work Plan, but says it is focusing on ingredients and endpoints associated with children, women of childbearing age, communities of color and aquatic impacts.